Resources

We've amended our petition for review against the FTC for allowing the sale of unfixed, recalled used cars

The Federal Trade Commission (FTC) has now filed unacceptable consent decrees with 3 more used car dealers, which we and our co-plaintiffs Center for Auto Safety and Consumers for Automobile Reliability and Safety (CARS) consider to be in violation of several provisions of law. We claim that the agency’s decisions to allow such demonstrably unsafe used vehicles to be sold to the public as “safe,” “repaired for safety issues,” or “subject to a rigorous inspection” violate several provisions of law. So we've updated our petition for review to the DC Circuit, U.S. Court of Appeals to challenge a total of 6 (not 3) of the agency's actions.

Our amicus brief in "English v. Trump and Mulvaney," CFPB leadership case

This is an amicus (or friend of the court) brief filed in U.S. District Court in support of plaintiff Leandra English, appointed acting director of the Consumer Financial Protection Bureau (CFPB) by outgoing director Richard Cordray. It was filed today by Public Citizen, Americans for Financial Reform, U.S. PIRG Education Fund and other leading consumer organizations in support of a motion seeking a preliminary injunction concerning who is the lawful acting director of the Consumer Bureau. Leandra English seeks to block the president's conflicting appointment of White House Office of Management and Budget director Mick Mulvaney to be acting CFPB director, (while incidentally also continuing to run OMB). The case is Leandra English vs. Donald J. Trump and John M. Mulvaney.

Nuclear Power and the Threat to Drinking Water

In the United States, 49 million Americans receive their drinking water from surface sources located within 50 miles of an active nuclear power plant.

Consumer Brief Supporting NY Attorney General In Alzheimer's Drug Case

In December, a U.S. judge upheld the New York Attorney General's request for an injunction requiring the powerful Big Pharma company Actavis to continue marketing a lower-cost version of its Alzheimer's drug Namenda, instead of using a "product-hopping" scheme to move consumers to a newer but virtually identical version that would enjoy monopoly protection until 2029, making it unlikely that lower-cost generic alternatives could successfully enter the market. We joined other leading groups, including Consumers Union and Public Citizen, in a friend-of-the-court brief to the U.S. Second Circuit Court of Appeals supporting General Eric Schneiderman's defense against Actavis in its appeal. Our brief is attached.

Pages

Subscribe to More Resources

DEFEND THE CFPB

Tell your senators to oppose the “Financial CHOICE Act,” which would gut Wall Street reforms and destroy the Consumer Financial Protection Bureau as we know it.

Support Us

Your donation supports U.S. PIRG’s work to stand up for consumers on the issues that matter, especially when powerful interests are blocking progress.

Consumer Alerts

Join our network and stay up to date on our campaigns, get important consumer updates and take action on critical issues.
Optional Member Code